Short- and long-term effects of oral vancomycin on the human intestinal microbiota
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Short- and long-term effects of oral vancomycin on the human intestinal microbiota
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 72, Issue 1, Pages 128-136
Publisher
Oxford University Press (OUP)
Online
2016-10-06
DOI
10.1093/jac/dkw383
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection
- (2015) Marco Falcone et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Differences of the Fecal Microflora With Clostridium difficile Therapies
- (2015) T. J. Louie et al. CLINICAL INFECTIOUS DISEASES
- Determining the Long-term Effect of Antibiotic Administration on the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods
- (2015) Mamun-Ur Rashid et al. CLINICAL INFECTIOUS DISEASES
- Loss of Microbiota-Mediated Colonization Resistance toClostridium difficileInfection With Oral Vancomycin Compared With Metronidazole
- (2015) Brittany B. Lewis et al. JOURNAL OF INFECTIOUS DISEASES
- The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment
- (2015) Xuan Zhang et al. NATURE MEDICINE
- Antibiotics in Early Life Alter the Gut Microbiome and Increase Disease Incidence in a Spontaneous Mouse Model of Autoimmune Insulin-Dependent Diabetes
- (2015) Sophie Candon et al. PLoS One
- Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity
- (2013) Anne Vrieze et al. JOURNAL OF HEPATOLOGY
- Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole
- (2013) Turki Abujamel et al. PLoS One
- Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment
- (2013) M Million et al. Nutrition & Diabetes
- Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis
- (2013) Jose U Scher et al. eLife
- Sustained Clinical Response as an Endpoint in Treatment Trials of Clostridium difficile-Associated Diarrhea
- (2012) Stuart Johnson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
- (2012) T. J. Louie et al. CLINICAL INFECTIOUS DISEASES
- Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma
- (2012) Shannon L Russell et al. EMBO REPORTS
- Antibiotics, microbiota, and immune defense
- (2012) Carles Ubeda et al. TRENDS IN IMMUNOLOGY
- Normal gut microbiota modulates brain development and behavior
- (2011) R. D. Heijtz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gut-Residing Segmented Filamentous Bacteria Drive Autoimmune Arthritis via T Helper 17 Cells
- (2010) Hsin-Jung Wu et al. IMMUNITY
- Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans
- (2010) Carles Ubeda et al. JOURNAL OF CLINICAL INVESTIGATION
- A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin
- (2010) G. W. Tannock et al. MICROBIOLOGY-SGM
- Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
- (2009) Ivaylo I. Ivanov et al. CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started